section name header

Indications

REMS

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypertension.

Derm: rash.

GI: diarrhea.

GU: urinary frequency.

Hemat: anemia.

Metab: weight gain.

Neuro: dizziness, fatigue, headache, sedation.

Interactions

Drug-Drug:

Availability

(Generic available)

Route/Dosage

Renal Impairment

  • (Adults): CCr 5–29 mL/min: Immediate-release (solution): Target dose is 10 mg/day (5 mg twice daily); Extended-release: Target dose is 14 mg once daily.

US Brand Names

Namenda, Namenda XR

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: anti-Alzheimers's agents

Pharmacologic Classification: n methyl d aspartate antagonist

Pharmacokinetics

Absorption: Well absorbed after oral administration.

Distribution: Unknown.

Metabolism/Excretion: 57–82% excreted unchanged in urine by active tubular secretion moderated by pH dependent tubular reabsorption. Remainder metabolized; metabolites are not pharmacologically active.

Half-life: 60–80 hr.

Canadian Brand Names

Ebixa

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown3–7 hr12 hr
PO-ERunknown9–12 hr24 hr

Patient/Family Teaching

Pronunciation

me-MAN-teen

Code

NDC Code*